Personalizing Treatments and Patient Education

Author(s):

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA,Amir Ali, PharmD, BCOP

Key Takeaways

Personalizing treatment regimens involves adjusting dosing schedules and administration routes to improve adherence and quality of life.
Evaluating patient-specific factors, such as lifestyle and preferences, is crucial in developing personalized treatment plans.
Pharmacists provide essential resources and support, including medication counseling and adherence tools, to enhance patient engagement.
Collaborative efforts between healthcare providers and pharmacists are vital for optimizing treatment plans and improving patient outcomes.

Panelists discuss how treatment regimens for multiple myeloma patients can be personalized to improve adherence and quality of life by considering factors such as dosing schedules and routes of administration while emphasizing the role of pharmacists in providing resources and support to keep patients informed, engaged, and compliant with their individualized treatment plans.

EP: 1.Treatment Landscape for Transplant-Eligible Patients with NDMM

EP: 2.Frontline Treatment and Sequencing Therapy

EP: 3.Impact of Transplant Eligibility on Treatment Selection

EP: 4.Treatment Regimen Considerations

EP: 5.Impact of IFM 2009 and DETERMINATION Studies

EP: 6.Key End Points in Clinical Trials

EP: 7.Real-World Considerations for New Therapies

EP: 8.Challenges in Adopting Novel Therapies

EP: 9.Evaluating New Data for Transplant-Eligible Patients With NDMM: PERSEUS, IsKia, and GMMG HD7

EP: 10.Impact of SC Daratumumab

EP: 11.SC vs IV Administration Methods

EP: 12.Pharmacists’ Roles in MM Management

EP: 13.Pharmacists’ Roles on the Multidisciplinary Team

Now Viewing

EP: 14.Personalizing Treatments and Patient Education

EP: 15.Addressing Payer Coverage Challenges

EP: 16.Unmet Needs for Transplant-Eligible NDMM

Video content above is prompted by the following:

How can a patient's treatment regimen be personalized to improve adherence and quality of life (eg, dosing schedule, route of administration), and how are those factors weighed or evaluated when developing treatment plans?
(Dr Adams) What resources or support can pharmacists offer to keep patients informed, engaged, and compliant with their treatment plans?